AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-PTSD
Description: CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT-PTSD
Description: CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT
Description: TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
Study NCT03557502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Therapy Group
Description: 30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
Study NCT03557502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group
Description: 30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
Study NCT03345680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referred to a specific hospital for treatment
Description: To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
Study NCT04774016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test formula A without added pre- and pro-biotic
Description: An identical formula as test formulas fortified with 2.20 mg iron as FeSO4-58 and 0.05 mg native iron per serving (235 ml), but without added pre- or probiotic.
Study NCT04774016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula B with synbiotic
Description: Test formula fortified with 2.20 mg iron as FeSO4-57 and 0.05 mg native iron per serving (235 ml) and added synbiotic.
Study NCT04774016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula C with HMOs
Description: Test formula fortified with 2.20 mg iron as FeSO4-54 and 0.05 mg native iron per serving (235 ml) and added HMOs.
Study NCT04078321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mollii ®
Description: The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
Study NCT00668941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
Study NCT00668941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Participants will take 70 mg per week of alendronate for 48 months.
Study NCT00668941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Participants will take 70 mg per week of alendronate for 48 months.
Study NCT00668941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
Study NCT00303719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
Study NCT00303719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of >200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD791
Description: Temanogrel
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel
Study NCT00303719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 30 mg/m\^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m\^2 for 5 days.
Study NCT00303719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if \< 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) > 0.5 x 109 /L).
Study NCT00668941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
Study NCT00668941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel
Study NCT00668941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
Study NCT00303719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
Study NCT00303719 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: The dose of TBI will be 200 cGy given in a single fraction on day -1.
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin
Study NCT00303719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients with white blood cell (WBC) counts \< 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) > 2500 for 2 consecutive days.
Study NCT00515866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral
Study NCT00515866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous injection
Study NCT03283813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
Study NCT03283813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
Study NCT03283813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
Study NCT02275949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
Study NCT02275949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
Study NCT02275949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture
Description: Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
Study NCT02275949 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation
Description: Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
Study NCT02275949 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham intradermal acupuncture
Description: Intradermal acupuncture needles are put over the tape not penetrating the skin.
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for APD791
Description: Placebo for APD791
Study NCT00402961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
Study NCT00402961 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
Study NCT03103789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: single catheter mucosal impedance testing
Study NCT03044808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT03103789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: balloon assembly mucosal impedance testing
Study NCT01147861 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 5mg in the AM and 5mg in the PM
Study NCT01147861 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 10mg in the AM
Study NCT01147861 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 50mg in the AM
Study NCT01147861 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: 25mg in the AM and 25mg in the PM
Study NCT03044808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02927938 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic HCT
Description: Allogeneic HCT
Study NCT02927938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation chemotherapy
Description: Cytarabine-based consolidation chemotherapy
Study NCT04129892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In Favor of My Resilient Self Academic course
Description: Assessing the effect of an academic course on student's emotional resilience.
Study NCT02468349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
Study NCT02199561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal transplant processed from routinely screened universal donor
Study NCT02340910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Duration
Description: During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
Study NCT02340910 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long Duration
Description: During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks .
Study NCT02653547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard multisite four weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
Study NCT02653547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-frequency multisite four weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
Study NCT01147861 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets in the AM and 2 placebo tablets in the PM
Study NCT03406858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2Bi-Armed Activated T Cells
Description: Given IV
Study NCT03406858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03406858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04945629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation with a PRP (PRGF-Endoret)
Description: Filling of the alveolus with PRGF clot and fibrin plug.
Study NCT04945629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood clot and simple suture
Description: Filling the alveolus with blood clot
Study NCT02248350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised and Home Based Exercise
Description: Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
Study NCT02248350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control Group
Description: Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
Study NCT02881242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02881242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02881242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT02672423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Capsules (Reference Formulation)
Description: Administered orally
Study NCT02672423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib Tablet (Test Formulation)
Description: Administered orally
Study NCT03832621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
Study NCT03832621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg i.v. every 4 weeks
Study NCT03832621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
Study NCT03870828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoalveolar lavage and taking bronchial mucosa samples
Description: Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved.
Study NCT03870828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6minute walk test
Description: a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
Study NCT03870828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas
Description: If SpO2 is measured to be \< 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
Study NCT03870828 — intervention group
Intervention type: PROCEDURE
Intervention: Blood drawing
Description: A vein will be punctured in order to take a blood sample for further tests
Study NCT03936361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
Study NCT03769090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol
Study NCT03769090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
Description: Budesonide/albuterol sulfate combination inhalation aerosol
Study NCT03469479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Study NCT03469479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic resection
Description: R0 resection
Study NCT03469479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: R0 resection
Study NCT03769090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol sulfate metered-dose inhaler 180 μg
Description: Albuterol sulfate inhalation aerosol
Study NCT02653547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard multisite two weeks
Description: Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).